The panel recommended increased investments in health research to provide affordable and quality healthcare and noted that in the USA, the budget of National Institute of Health, which functions like that of Indian Council of Medical Research (ICMR) under DHR, is 32 billion dollars per year.
The parliamentary panel also supported the DHR's demand for additional funds to the tune of Rs 835 crore for 2017-18.
"The actual expenditure was Rs 3,180.99 crore up to February, 2017. The committee observes that there is a huge mismatch to the tune of Rs 6,762.50 crore between 12th Plan outlay and the RE allocation made to the department," it said.
India's rapidly growing economy has thrown up huge health challenges and DHR has a "crucial" role to play in ensuring healthcare service to the population by way of generation of new knowledge and its translation into health projects.
"The government owes an explanation to the committee on the reasons behind such a huge gap between the budgetary allocation made to DHR from 2012-13 to 2016-17 and the total approved outlays for the 12th Five Year Plan and its impact on the department's vision to bring modern technology to the people through innovations," it said.
"The department has informed that it (funds constraint) has impacted implementation of DHR's schemes by restricting sanctioning of new units on priority, providing recurring grants to ongoing ones, upgrading ICMR's health research infrastructure and pendency of extramural proposals due to non availability of budgetary allocations," the panel said.
in India are "huge and complex" due to its large population, rapid industrialisation, demographic transition, huge maternal and infant mortality and high burden of diseases.
To address the high disease burden, the national health research agenda needs to be updated constantly and indigenous health products would need to be developed to combat these challenges, the panel said.
"A paradigm shift in pursuing the national research agenda will therefore need to be made to address these challenges but this is not possible with the current low budget allocation to DHR," it said.
"The committee also takes note of the (health) secretary's submission that it takes two and a half billion dollars to develop a new drug from scratch and it needs thousands of scientists working on it at different stages," the panel said.
"The committee lends its support to the department's demand for additional funds to the tune of Rs 835 crore for 2017-18 and recommends that the finance ministry should increase the budgetary allocation to the DHR so that it is able to ensure continuity in critical healthcare research," it said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
